Expression Pathology, Flagship Partner to Offer Translational Biomarker Services | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Expression Pathology and Flagship Biosciences today announced a service partnership to enable tissue translational biomarker development, validation, and application to support new drug development.

The new offering combines Expression's expertise in multiplex tissue proteomic assays using frozen formalin, paraffin-fixed tissues with Flagship's pathology expertise.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: map of UV-induced damage in yeast genome, comparative epigenomics uncovers plant lacking key DNA methyltransferase enzyme, and more.

Researchers kick off their second Queer in STEM survey to examine what can make STEM careers welcoming, Wired reports.

A startup company is offering a test to analyze soil samples from farms for pathogens.

Prosecutors seek to introduce evidence from low-template DNA analysis in a murder case in upstate New York, the New York Times reports.